Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Expert Market Research Explores the Top 4 Companies in the Asia Pacific COVID-19 Diagnostics Market

Top 4 Companies in the Asia Pacific COVID-19 Diagnostics Market


Guangzhou Wondfo Biotech Co., Ltd., SolGent Co., Ltd., Biolidics Limited, PT Bio Farma (Persero), Beijing Jinwofu Bioengineering Technology Co., Ltd., Mylab Discovery Solutions Pvt. Ltd., and Ellume Limited, among others are the major players in the Asia Pacific COVID-19 diagnostics market.


The Asia Pacific COVID-19 diagnostics market is being aided by the growing cases of COVID-19 in India and China, which have performed around 234 million and 160 million tests, respectively, for COVID-19 as of March 2021.

With an increase in the number of COVID-19 positive cases, the demand for COVID-19 diagnostics is increasing, with China initially being the hardest hit due to its relatively larger population density. Due to the rapid spread of coronavirus in India, it emerged as the worst-affected country in Asia Pacific. Many countries in Asia and the Pacific are scrambling to improve their scanning and research capacities. Many significant biotech and pharmaceutical companies have produced their own COVID-19 diagnostics, and many more are saving, researching, and developing newer and more advanced COVID-19 diagnostics. This is expected to result in promising corporate growth in the next years. Government measures that help detection kit manufacturers are allowing them to increase manufacturing volume, which is anticipated to boost the industry growth.


Read more about this report - REQUEST FREE SAMPLE COPY IN PDF


The market for nasopharyngeal swabs is predicted to generate the most income. Susceptibility to SARS-CoV-2, detection rate, and viral load have all been found to be much higher in nasopharyngeal swabs than in other types of swabs. As a result, this swab type is most commonly used to check for COVID-19 and determine SARS-CoV-2 burden, resulting in the highest revenue share in the sector. Due to growing demand and availability of nasopharyngeal swabs, this segment is likely to grow at a profitable rate during the forecast period.


Top 4 Asia Pacific COVID-19 Diagnostics Companies:

Biolidics Limited

Establishment: 2009    
Headquarter: Singapore
Website: https://www.biolidics.cgtgsom/

Incorporated in 2009 and listed on the Singapore Stock Exchange, Biolidics Limited  is a precision medical technology company with a focus on developing a portfolio of innovative diagnostic solutions to lower healthcare costs and improve clinical outcomes. The company has developed and commercialised a fully automated IVD medical device, the ClearCell FX1 System, which relies on a novel patented technology to separate and enrich cancer cells from the blood.


PT Bio Farma (Persero)

Establishment: 1890
Headquarter: Indonesia

PT Bio Farma (Persero) is an Indonesian state-owned enterprise based in Bandung and the only local vaccine manufacturer in Indonesia, which produces vaccines and sera to support immunisation in Indonesia and other countries. Bio Farma vaccine produces vaccines against measles, polio, hepatitis B, and pentavalent vaccine. The vaccines have been supplied to multiple countries through UNICEF, PAHO, and other organisations.


Mylab Discovery Solutions Pvt. Ltd.

Establishment: 2016
Headquarter: Pune, India

Mylab Discovery Solutions Pvt. Ltd. is an Indian molecular biology company that develops and commercialises tests used in human diagnostics, food safety, agriculture, and veterinary medicine, empowering labs to obtain reliable, timely, and actionable results. It is the first company in Asia and second company worldwide to develop and manufacture FDA-approved ID-NAT kits for accurate detection of HIV, HBV, HCV, and other infections.



Establishment: 2010
Headquarter: Australia

Despite advances in modern medicine, infectious diseases continue to pose a significant threat to humanity. Ellume was founded to address these problems through innovative approaches to diagnosis and treatment accessibility. The technology Ellume developed to meet this need consists of several layers of innovation. Investment in the core science has been significant and has resulted in multiple patent families. Around this core science, Ellume wrapped simple, intuitive user interfaces with smart-device connectivity to create unique products. The company develop, manufacture, and commercialise the next generation of digital diagnostic products for healthcare professionals and consumers.

Also Read@ Asia Pacific COVID-19 Diagnostics Market to Witness a Considerable Growth During 2021-2026, Aided by the Rising COVID-19 Cases especially in India and China

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Latest Blogs